Literature DB >> 20467232

The polymorphism in aldehyde dehydrogenase-2 gene is associated with elevated plasma levels of high-sensitivity C-reactive protein in the early phase of myocardial infarction.

Yuan Bian1, Yu-guo Chen, Feng Xu, Li Xue, Wen-qing Ji, Yun Zhang.   

Abstract

Aldehyde dehydrogenase-2 (ALDH2) is a key enzyme of alcohol metabolism, catalyzing the conversion of aldehyde to acetic acid. The G-to-A polymorphism in exon 12 of the ALDH2 gene, which causes Glu-to-Lys substitution at codon 504, has been shown to be an independent risk factor for acute myocardial infarction (AMI). We investigated the possible role of the G-to-A polymorphism in the severity of the myocardial damage in the early phase of AMI by measuring plasma levels of inflammatory markers, including high-sensitivity C-reactive protein (hs-CRP). A total of 226 Han Chinese patients with AMI were divided into two groups: subjects without A allele (GG, n = 144) and subjects with A allele (GA and AA, n = 82), and the blood samples were collected within 12 hours after the onset of AMI. The results displayed that high-density lipoprotein cholesterol (HDL-C) was higher in GG group than that in GA and AA group (p < 0.05). The body mass index (BMI) and the concentration of hs-CRP were lower in GG group than that in GA and AA group (p < 0.05). Multivariate logistic regression analysis showed that subjects with the A allele were at an increased risk for the high level of hs-CRP (> 3 mg/L) compared with those with GG genotype (OR = 4.908, 95% CI = 1.57 approximately 20.98). Thus, the A allele in ALDH2 gene is associated with the elevated plasma levels of hs-CRP after the onset of AMI, suggesting a higher susceptibility of the myocardium to ischemic injuries.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20467232     DOI: 10.1620/tjem.221.107

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  8 in total

1.  N-terminal valine adduct from the anti-HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo.

Authors:  C Charneira; N M Grilo; S A Pereira; A L A Godinho; E C Monteiro; M M Marques; A M M Antunes
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Enzymes and signal pathways in the pathogenesis of alcoholic cardiomyopathy.

Authors:  E Leibing; T Meyer
Journal:  Herz       Date:  2016-09       Impact factor: 1.443

3.  Asian flushing presents opportunities for disease prevention.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2016-11       Impact factor: 4.599

4.  Cardioprotection induced by a brief exposure to acetaldehyde: role of aldehyde dehydrogenase 2.

Authors:  Cintia Bagne Ueta; Juliane Cruz Campos; Rudá Prestes E Albuquerque; Vanessa Morais Lima; Marie-Hélène Disatnik; Angélica Bianchini Sanchez; Che-Hong Chen; Marisa Helena Gennari de Medeiros; Wenjin Yang; Daria Mochly-Rosen; Julio Cesar Batista Ferreira
Journal:  Cardiovasc Res       Date:  2018-06-01       Impact factor: 10.787

Review 5.  Targeting aldehyde dehydrogenase 2: new therapeutic opportunities.

Authors:  Che-Hong Chen; Julio Cesar Batista Ferreira; Eric R Gross; Daria Mochly-Rosen
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

Review 6.  The "Goldilocks Zone" from a redox perspective-Adaptive vs. deleterious responses to oxidative stress in striated muscle.

Authors:  Rick J Alleman; Lalage A Katunga; Margaret A M Nelson; David A Brown; Ethan J Anderson
Journal:  Front Physiol       Date:  2014-09-18       Impact factor: 4.566

7.  Isoflurane preconditioning confers cardioprotection by activation of ALDH2.

Authors:  Xiao-E Lang; Xiong Wang; Ke-Rang Zhang; Ji-Yuan Lv; Jian-Hua Jin; Qing-Shan Li
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

Review 8.  Could ALDH2*2 be the reason for low incidence and mortality of ovarian cancer for East Asia women?

Authors:  Shaomin Yan; Guang Wu
Journal:  Oncotarget       Date:  2017-12-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.